Therapy News and Research

RSS

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

Scientists identify new toxic entity associated with dementia and motor neuron disease

A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica.

31 Oct 2013

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.

31 Oct 2013

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

The National Cancer Institute's (NCI) new Provocative Questions research funding program has awarded a prestigious grant to a researcher at Roswell Park Cancer Institute (RPCI) to investigate a promising but neglected or unexplored area of cancer research.

31 Oct 2013

Multidisciplinary care critically important for prostate cancer patients

Only half of the men who receive a prostate cancer diagnosis in North Carolina consult with more than one type of physician before deciding on a course of treatment, according to research presented by University of North Carolina researchers at the 2013 American Society for Radiation Oncology annual meeting on Sept. 24.

31 Oct 2013

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine.

31 Oct 2013

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

HIV infection, not antiretroviral therapy (ART), is associated with risk for atherosclerosis in patients with no history of smoking, particularly those infected for eight years or more.

31 Oct 2013

Scientists develop new therapeutic approach for treatment of type 2 diabetes

Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.

31 Oct 2013

UofL researcher enters into license and research collaboration agreement with Novartis

The University of Louisville today announced that researcher Dr. Suzanne Ildstad, representing Regenerex LLC, has entered into a license and research collaboration agreement with Novartis to provide access to stem cell technology that has the potential to help transplant patients avoid taking anti-rejection medicine for life and could serve as a platform for treatment of other diseases.

31 Oct 2013

Courts in Texas, Okla. wrestle with state abortion laws

Oklahoma's high court on Tuesday set the stage for the U.S. Supreme Court to decide whether states can restrict doctors from prescribing two drugs used to induce abortion in the early stages of prnegancy.

30 Oct 2013

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.

30 Oct 2013

Qigong may help survivors of prostate cancer to combat fatigue

The flowing movements and meditative exercises of the mind-body activity Qigong may help survivors of prostate cancer to combat fatigue.

30 Oct 2013

Teleflex net revenues increase 12.4% to $413.8 million in third quarter 2013

Teleflex Incorporated today announced financial results for the third quarter ended September 29, 2013.

30 Oct 2013

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload. In a study published recently in Molecular Therapy, researchers found that giving subjects a treatment to temporarily rid the body of antibodies provides the virus safe passage to targeted cells, allowing it to release a corrective or replacement gene to treat disease.

30 Oct 2013

Janssen submits Marketing Authorization Application for Ibrutinib

Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.

30 Oct 2013

REDDSTAR plenary meeting to be held in Berlin on Nov 5 and 6

'Diabetes- can stem cells help?' is a free, public event that will be held on Monday, 4 November 2013 from 19:00- 20:30 at The Ruin located within the Berlin Museum of Medical History, Charité. Diabetes and stem cell researchers from around Europe will assemble for a REDDSTAR plenary meeting hosted by Charité in Berlin on November 5 and 6th.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

Overweight men diagnosed with prostate cancer more likely to die from the disease

Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.

30 Oct 2013

Therapy News and Research

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Viropharma announces financial results for third quarter 2013

Scientists identify new toxic entity associated with dementia and motor neuron disease

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

Multidisciplinary care critically important for prostate cancer patients

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

Scientists develop new therapeutic approach for treatment of type 2 diabetes

UofL researcher enters into license and research collaboration agreement with Novartis

Courts in Texas, Okla. wrestle with state abortion laws

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

Qigong may help survivors of prostate cancer to combat fatigue

Teleflex net revenues increase 12.4% to $413.8 million in third quarter 2013

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Janssen submits Marketing Authorization Application for Ibrutinib

REDDSTAR plenary meeting to be held in Berlin on Nov 5 and 6

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Overweight men diagnosed with prostate cancer more likely to die from the disease

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News